| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | LOR2; LOX L2; LOXL2; Lysyl oxidase homolog 2; Lysyl oxidase like 2; WS9 14;;LOXL2 |
| WB Predicted band size | Calculated MW: 87 kDa ; Observed MW: 53,106 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human LOXL2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
1. **"LOXL2 in cancer: regulation, downstream effectors and novel antibody-based therapies"**
- **Authors**: Smith A, et al.
- **摘要**: 探讨LOXL2在肿瘤转移和微环境重塑中的作用，综述了靶向LOXL2的单克隆抗体在抑制侵袭性癌症(如乳腺癌和胰腺癌)中的潜力，并讨论了抗体介导的阻断机制。
2. **"A LOXL2-specific antibody suppresses fibrosis in preclinical models of lung and liver disease"**
- **Authors**: Jones B, et al.
- **摘要**: 研究开发了一种高选择性抗LOXL2抗体，通过抑制胶原交联和基质硬化，显著减轻小鼠模型中肺纤维化和肝纤维化的病理进展。
3. **"Targeting LOXL2 with a humanized antibody-drug conjugate for triple-negative breast cancer therapy"**
- **Authors**: Chen L, et al.
- **摘要**: 报道了一种新型抗LOXL2抗体-药物偶联物(ADC)，在体外和体内实验中显示对三阴性乳腺癌细胞的选择性杀伤作用，并减少肿瘤转移。
4. **"LOXL2 promotes tumor angiogenesis through interaction with VEGFR2: therapeutic implications of a neutralizing antibody"**
- **Authors**: Wang Y, et al.
- **摘要**: 揭示LOXL2通过结合VEGFR2激活血管生成信号通路，开发的中和抗体在结直肠癌模型中抑制血管生成并延缓肿瘤生长。
(注：以上为示例文献，实际引用需查询具体数据库如PubMed或Google Scholar获取真实研究。)
Lysyl oxidase-like 2 (LOXL2) is a copper-dependent enzyme belonging to the lysyl oxidase family, primarily involved in remodeling the extracellular matrix (ECM) by catalyzing cross-linking of collagen and elastin. It plays critical roles in tissue homeostasis, fibrosis, and cancer progression. Dysregulation of LOXL2 has been implicated in pathological conditions such as organ fibrosis, tumor metastasis, and angiogenesis. In cancer, LOXL2 promotes epithelial-to-mesenchymal transition (EMT), enhancing tumor cell invasion and metastasis by modifying the tumor microenvironment.
LOXL2 antibodies are immunological tools designed to detect, quantify, or inhibit LOXL2 activity in research and therapeutic contexts. In research, these antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study LOXL2 expression patterns in tissues or cell lines, particularly in cancer and fibrotic disease models. Therapeutically, neutralizing LOXL2 antibodies have been explored to block ECM remodeling in fibrotic diseases or to inhibit metastatic pathways in cancers. For example, preclinical studies in breast, liver, and lung cancers suggest that LOXL2-targeting antibodies may reduce metastasis and improve survival outcomes.
Challenges include ensuring antibody specificity due to structural homology among LOXL family members and addressing isoform variability. Despite these hurdles, LOXL2 remains a promising target, with antibodies serving as both investigative tools and potential therapeutics in precision medicine.
×
